Novocure Ltd

NVCR49

$16.57arrow_drop_down7.43%-$1.33

NVCR49

$16.57

arrow_drop_down7.43%-$1.33

Performance History

Key Stats
Open	$18.08
Prev. Close	$18.19
EPS	-1.39
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	17.61	18.44
52 Week Range	10.87	24.73

Ratios







EPS	-1.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Novocure Ltd (NVCR)

Novocure Ltd (NVCR) is a global oncology company that develops and commercializes treatment therapies for cancer patients. The company's flagship product, Optune, is a non-invasive, portable device that delivers Tumor Treating Fields (TTFields) to inhibit cancer cell division and promote cell death. Novocure's unique treatment approach addresses the underlying biology of cancer cells and has shown promising results in multiple clinical trials.

Novocure's stock price history has demonstrated significant growth over the years. Since its initial public offering in 2015, the stock has steadily climbed, reflecting the growing demand for its innovative cancer treatment solutions. Investors have shown confidence in Novocure's ability to disrupt the oncology market and improve patient outcomes.

In recent news, Novocure announced positive results from a phase 3 clinical trial evaluating the efficacy of Optune in combination with chemotherapy for the treatment of newly diagnosed glioblastoma, a type of brain cancer. The trial demonstrated a significant improvement in overall survival, further validating the effectiveness of Novocure's treatment approach.

Industry analysts have also recognized Novocure's potential, highlighting its unique position in the oncology market. The company's proprietary technology and growing product portfolio set it apart from traditional cancer treatment methods, offering patients a new and effective therapeutic approach. Novocure's market cap has steadily increased as a result, reflecting investor confidence in its long-term growth prospects.

When comparing Novocure to its industry peers, the company stands out as a leader in innovative cancer treatment solutions. While traditional treatment approaches often come with significant side effects, Novocure's therapy is non-toxic and well-tolerated by patients. This advantage positions the company for continued success and market dominance.

Novocure's 52-week range demonstrates strong performance, with the stock trading at both its highest and lowest levels during this period. This volatility reflects the dynamic nature of the oncology market and the potential for rapid growth and fluctuations in demand for Novocure's products.

The stock's day range indicates the trading range of Novocure shares on a particular day. This range can vary depending on market conditions and investor sentiment. Novocure's trading volume, on the other hand, represents the number of shares traded in a given period. High trading volume often indicates increased investor interest and can be a positive sign for the stock's performance.

In summary, Novocure Ltd (NVCR) is a global oncology company that has experienced significant growth and success in the market. Its flagship product, Optune, is a groundbreaking cancer treatment technology that has shown promising results in clinical trials. Novocure's unique approach, utilizing Tumor Treating Fields, sets it apart from traditional treatment methods and offers a promising solution for cancer patients.

The company's stock price history reflects investor confidence in its innovative treatments and long-term growth prospects. Positive news from recent clinical trials further validates Novocure's effectiveness in improving patient outcomes. Industry analysts recognize Novocure as a leader in the oncology market, with a unique position and growing product portfolio.

Novocure's market cap has steadily increased as a result of its success, demonstrating strong investor interest and confidence. When compared to its industry peers, Novocure stands out as a leader in providing non-toxic and well-tolerated cancer treatment solutions.

The stock's 52-week range demonstrates its volatility and potential for rapid growth and fluctuations. Daily trading ranges and trading volume can provide insights into market conditions and investor sentiment towards the stock. Overall, Novocure Ltd (NVCR) continues to be a prominent player in the global oncology market, offering innovative cancer treatment options to improve patient outcomes.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Mr. Asaf Danziger
Headquarters: Saint Helier
Employees: 1320
Exchange: NASDAQ

Keep an eye on Novocure Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

Is Novocure Ltd (NVCR) a growth stock?

Novocure Ltd (NVCR) has shown an average price growth of -3.55% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Novocure Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Novocure Ltd (NVCR) stock price performance year to date (YTD)?

As of the latest data, Novocure Ltd (NVCR) has a year-to-date price change of 15.07%. Over the past month, the stock has experienced a price change of 3.18%. Over the last three months, the change has been -9.08%. Over the past six months, the figure is -7.84%. Looking at a longer horizon, the five-year price change stands at -79.59%.

help

What is Novocure Ltd's (NVCR) price per share?

The current price per share for Novocure Ltd (NVCR) is $16.57. The stock has seen a price change of -$1.33 recently, indicating a -7.43% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Novocure Ltd (NVCR)?

For Novocure Ltd (NVCR), the 52-week high is $24.74, which is 49.28% from the current price. The 52-week low is $10.87, the current price is 52.44% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Novocure Ltd (NVCR) a profitable company?

Novocure Ltd (NVCR) has a net income of -$207.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 74.81% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -20.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $509.34M, although specific revenue growth data is currently not available. The gross profit is $381.06M. Operating income is noted at -$232.87M. Furthermore, the EBITDA is -$140.61M.

help

What is the market capitalization of Novocure Ltd (NVCR)?

Novocure Ltd (NVCR) has a market capitalization of $1.87B. The average daily trading volume is 16.82, indicating the stock's liquidity and investor engagement.